Cephalosporin prodrug substrates

Cephalosporin prodrug substrates are chemical derivatives of cephalosporin antibiotics designed to enhance pharmacokinetic properties, such as oral absorption or systemic distribution (Source: PubMed, PMID: 11033418). These molecules are pharmacologically inactive until they undergo biotransformation, typically through enzymatic cleavage of an ester or phosphate group by host or bacterial enzymes (Source: StatPearls, Cephalosporins). Once activated, the resulting cephalosporin molecule targets Penicillin-Binding Proteins (PBPs) on the bacterial cell wall, leading to the inhibition of peptidoglycan cross-linking and eventual bacterial cell lysis (Source: Merck Manual). This approach is commonly used to improve the bioavailability of drugs that are otherwise poorly absorbed in the gastrointestinal tract or to facilitate targeted delivery in specialized therapeutic contexts like Antibody-Directed Enzyme Prodrug Therapy (ADEPT) (Source: Journal of Medicinal Chemistry). While highly effective against a broad range of Gram-positive and Gram-negative bacteria, their use is limited by the emergence of beta-lactamase-mediated resistance and potential hypersensitivity in sensitive patients (Source: NIH, Antibiotic Resistance).

Other names

Cephalosporin prodrugsBeta-lactam prodrugsCef-prodrugsCephalosporin derivatives

Cephalosporin prodrugs are pharmacologically inactive molecules that undergo enzymatic hydrolysis (typically by esterases or phosphatases) in the body to release the active cephalosporin moiety, which then binds to and inhibits Penicillin-Binding Proteins (PBPs), preventing bacterial cell wall synthesis (Source: StatPearls, Cephalosporins).